Works matching IS 19466234 AND DT 2022 AND VI 14 AND IP 648

Results: 6

A step forward for LRRK2 inhibitors in Parkinson's disease.
Published in:
Science Translational Medicine, 2022, v. 14, n. 648, p. 1, doi. 10.1126/scitranslmed.abq7374
By:
- Lewis, Patrick A.
Publication type:
Article
Risk assessment with gut microbiome and metabolite markers in NAFLD development.
Published in:
Science Translational Medicine, 2022, v. 14, n. 648, p. 1, doi. 10.1126/scitranslmed.abk0855
By:
- Leung, Howell;
- Long, Xiaoxue;
- Ni, Yueqiong;
- Qian, Lingling;
- Nychas, Emmanouil;
- Siliceo, Sara Leal;
- Pohl, Dennis;
- Hanhineva, Kati;
- Liu, Yan;
- Xu, Aimin;
- Nielsen, Henrik B.;
- Belda, Eugeni;
- Clément, Karine;
- Loomba, Rohit;
- Li, Huating;
- Jia, Weiping;
- Panagiotou, Gianni
Publication type:
Article
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.
Published in:
Science Translational Medicine, 2022, v. 14, n. 648, p. 1, doi. 10.1126/scitranslmed.abj2658
By:
- Jennings, Danna;
- Huntwork-Rodriguez, Sarah;
- Henry, Anastasia G.;
- Sasaki, Jennifer C.;
- Meisner, René;
- Diaz, Dolores;
- Solanoy, Hilda;
- Wang, Xiang;
- Negrou, Elvira;
- Bondar, Vitaliy V.;
- Ghosh, Rajarshi;
- Maloney, Michael T.;
- Propson, Nicholas E.;
- Zhu, Yuda;
- Maciuca, Romeo D.;
- Harris, Laura;
- Kay, Angela;
- LeWitt, Peter;
- King, T. Alex;
- Kern, Drew
Publication type:
Article
Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression.
Published in:
Science Translational Medicine, 2022, v. 14, n. 648, p. 1, doi. 10.1126/scitranslmed.abh1261
By:
- Mao, Chengqiong;
- Yeh, Stacy;
- Fu, Juan;
- Porosnicu, Mercedes;
- Thomas, Alexandra;
- Kucera, Gregory L.;
- Votanopoulos, Konstantinos I.;
- Tian, Shaomin;
- Ming, Xin
Publication type:
Article
Gene therapy targeting protein trafficking regulator MOG1 in mouse models of Brugada syndrome, arrhythmias, and mild cardiomyopathy.
Published in:
Science Translational Medicine, 2022, v. 14, n. 648, p. 1, doi. 10.1126/scitranslmed.abf3136
By:
- Yu, Gang;
- Chakrabarti, Susmita;
- Tischenko, Miroslava;
- Chen, Ai-Lan;
- Wang, Zhijie;
- Cho, Hyosuk;
- French, Brent A.;
- Naga Prasad, Sathyamangla V.;
- Chen, Qiuyun;
- Wang, Qing K.
Publication type:
Article
Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension.
Published in:
Science Translational Medicine, 2022, v. 14, n. 648, p. 1, doi. 10.1126/scitranslmed.abe5407
By:
- Chelladurai, Prakash;
- Kuenne, Carsten;
- Bourgeois, Alice;
- Günther, Stefan;
- Valasarajan, Chanil;
- Cherian, Anoop V.;
- Rottier, Robbert J.;
- Romanet, Charlotte;
- Weigert, Andreas;
- Boucherat, Olivier;
- Eichstaedt, Christina A.;
- Ruppert, Clemens;
- Guenther, Andreas;
- Braun, Thomas;
- Looso, Mario;
- Savai, Rajkumar;
- Seeger, Werner;
- Bauer, Uta-Maria;
- Bonnet, Sébastien;
- Pullamsetti, Soni Savai
Publication type:
Article

Works matching IS 19466234 AND DT 2022 AND VI 14 AND IP 648

A step forward for LRRK2 inhibitors in Parkinson's disease.

Risk assessment with gut microbiome and metabolite markers in NAFLD development.

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.

Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression.

Gene therapy targeting protein trafficking regulator MOG1 in mouse models of Brugada syndrome, arrhythmias, and mild cardiomyopathy.

Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension.